Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients

NCT04920747 · clinicaltrials.gov ↗
COMPLETED
Status
65
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Centre Hospitalier Universitaire de Besancon